Salazar LR, Ibarra GAL, Iduma MM, Leyva BR

Language: Spanish
References: 9
Page: 608-614
PDF size: 324.73 Kb.

ABSTRACT

Background: During the second trimester of 21 trisomy pregnancies, median of maternal serum concentrations of alpha-fetoprotein, not conjugated estriol, beta fraction, and inhibin A differ from normal values, and it can be used to select high risk patients. Objective: To evaluate specificity of different forms of second trimester biochemical markers association in a group of healthy pregnant women and determine levels considered as low risk. Patients and methods: Random and cross-sectional study in 363 pregnant women with prenatal diagnosis to evaluate specificity of different combinations of biochemical markers. Down’s syndrome and defects of neural tube rates of detection were defined as the percentage of pregnancies with tests of detection of true negatives and false positives. Results: Total beta fraction has differences during weeks 13 to 14, with 70% of cases between 23,000 to 70,000 units, with 1.38% of false positives; alpha-fetoprotein fluctuated between 22 to 30 units, with 5.2% of false positives; conjugated estriol increases between 1.2 to 2.2 units during 2nd quarterly, with 6.3% of false positives; and inhibin has an increase, with 70% of cases located between 125 to 486.5 units, with 10.44% of false positives.. Conclusions: Marker formula with greater specificity was type IV, included alpha-fetoprotein, not conjugated estriol and beta fraction. In the isolated form, alpha-fetoprotein marker demonstrates greater specificity.

REFERENCES

1. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of cromosomal abnormalities. Am J Obstet Gynecol 2004;191:45-67.

2. Wold NJ, Watt HC, Hackshaw AK. Integrated screening for Down syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.

3. Herrera MM, Marcela BD, Pascual RV. Utilidad de la alfa feto proteína en la determinación del riesgo de embarazos portadores de síndrome de Down. R Cubana de Genética Humana 2000;2(2).

4. Aranda GJE, Barrón VJ, De la Luna PL, Corona LC, Kably AA. Utilidad clínica del cuádruple marcador bioquímico para predecir el desarrollo de complicaciones obstétricas. Ginecol Obstet Mex 1999;67:18-22.

5. Dawson-Saunders B, Trapp RG. Bioestadística médica. México: El Manual Moderno, 1997;pp:151-66.

6. Benn PA, Ying J, Beagoglon T, Egnan JF. Estimates for de sensitivity and false positive for second trimester serum screening for Down syndrome and trisomy 18 with adjustment crose identification and double-positive results. Prenat Diagn 2001;21(1):46-51.

7. Herrera MM, Marcelo DB, Pascual RV. Utilidad de la alfa-feto proteína en la determinación del riesgo de embarazos portadores de síndrome de Down. Revista Cubana de Genética Humana 2000;2(2)

8. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Medline 2001;75(1):46-52.

9. Dyce GE, Moras BF, León VM, Conde DO. Evaluación del programa de diagnóstico prenatal de las malformaciones congénitas por cuantificación de la alfafetoproteína. Rev Cubana Investigación Biomédica 2003:22(1):5-10.